Jose Royo, Andalusian Center for Development Biology, Spain Determining the role of genetic variations in the development of human diseases and using this information to develop better drug targets Royo's group, then at Spanish biotech start-up Neocodex, had no SNP genotyping platform, so sequencing was affordable on the low scale, and he generally ran 5-15 SNPs in 1,000-2,000 samples. However, when medium-throughput projects arose, Royo's group faced the problem of genotyping 50-200 SNPs in 500 samples.
展开▼
